Related Experiment Video

Updated: Aug 30, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs

Michiaki Kohno1, Jacques Pouyssegur

  • 1Laboratory of Cell Regulation, Department of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-14, Bunkyo-machi, Nagasaki 852-8521, Japan.

Progress in Cell Cycle Research
|November 5, 2003
PubMed

Insights

Targeting the ERK signaling pathway, crucial for cell growth and survival, offers a promising strategy for anticancer therapy. This review details advanced inhibitors and their mechanisms for cancer treatment.

Area of Science:

  • Cellular signaling pathways
  • Molecular oncology
  • Drug discovery

Background:

  • The ERK (extracellular signal-regulated kinase) signaling pathway, also known as the p42/p44 MAP kinase pathway, regulates critical cellular processes including growth, differentiation, and survival.
  • Dysregulation of the ERK pathway is frequently observed in various human tumors, highlighting its significance in cancer development.
  • The Ras-MAPK pathway, with ERK as a key component, is a validated target for therapeutic intervention in oncology.

Purpose of the Study:

  • To review the rationale for targeting the ERK signaling pathway in cancer therapy.
  • To present and discuss advanced inhibitors of the ERK pathway.
  • To explore the potential of combining ERK inhibitors with conventional cytotoxic agents.

Main Methods:

  • Literature review of preclinical and clinical studies on ERK pathway inhibitors.
  • Analysis of inhibitor specificity and mechanisms of action.
  • Evaluation of combination therapy strategies involving ERK inhibitors.

Main Results:

  • The ERK pathway is a critical node in cancer cell proliferation and survival, making its components attractive therapeutic targets.
  • Several classes of ERK pathway inhibitors have been developed, demonstrating varying degrees of specificity and efficacy.
  • Combination therapies involving ERK inhibitors and cytotoxic agents show potential for enhanced antitumor activity.

Conclusions:

  • Targeting the ERK signaling pathway, alone or in combination with cytotoxic drugs, represents a viable strategy for developing novel anticancer therapies.
  • Understanding the specificity and mechanisms of advanced ERK inhibitors is crucial for optimizing their clinical application.
  • Further research into combination strategies may lead to improved treatment outcomes for cancer patients.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...